In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-8. (cancelled)

9. (previously presented) A method of treating irritable bowel syndrome which comprises administering to a patient in need thereof a compound having NMDA receptor antagonist activity or a pharmaceutically acceptable salt thereof.

10. (withdrawn) A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound having NMDA receptor antagonist activity and a pharmaceutically acceptable carrier.

11. (withdrawn) The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor antagonist activity is a non-competitive NMDA receptor antagonist.

12. (withdrawn) The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor antagonist activity is a compound of formula (I) or a metabolite or isomer thereof



(I)

where:

R^1 and R^2 are independently phenyl or 4-fluorophenyl;

R^3 is hydrogen, C_{1-6} alkyl or methoxycarbonyl;

R^4 is hydrogen or methyl;

as a free base or a pharmaceutically acceptable salt thereof.

13. (previously presented) The method according to claim 9 wherein the compound is a non-competitive NMDA receptor antagonist.

14. (previously presented) The method according to claim 9 wherein the compound is a compound of formula (I) or a metabolite or isomer thereof



(I)

where:

R^1 and R^2 are independently phenyl or 4-fluorophenyl;

R^3 is hydrogen, C_{1-6} alkyl or methoxycarbonyl;

R^4 is hydrogen or methyl;

as a free base or a pharmaceutically acceptable salt thereof.

15. (previously presented) The method according to claim 14 wherein the compound is remacemide or a pharmaceutically acceptable salt thereof.

16. (previously presented) The method according to claim 14 wherein the compound is 2,3-diphenyl-2-propylamine or a pharmaceutically acceptable salt thereof.

17. (previously presented) The method according to claim 14 wherein the compound is (S)-1-phenyl-2-(2-pyridyl)ethanamine or a pharmaceutically acceptable salt thereof.

18. (previously presented) The method according to claim 9 wherein the compound is memantine or a pharmaceutically acceptable salt thereof.

19. (previously presented) The method according to claim 9 wherein the compound is 2-amino-N-(1,2-diphenylethyl)acetamide, alpha-phenyl-1H-pyrazole-1-ethanamine, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine, or 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine or a pharmaceutically acceptable salt thereof.